Skip to main content
. 2021 Mar;50(3):520–530. doi: 10.18502/ijph.v50i3.5593

Table 5:

Univariate analysis of poor prognosis in children with epilepsy [n(%), x̄±sd]

Factors n Effective group (n=71) Ineffective group (n=12) χ2/t P
Gender 0.001 0.971
Male 55 45(81.82) 10(18.18)
Female 28 23(82.14) 5(17.86)
Age (yr) 0.013 0.989
83 8.72±7.33 8.69±7.44
Course of disease (year) 1.061 0.318
83 1.2±0.3 1.3±0.4
Weight (kg) 0.055 0.956
83 15.32±8.12 15.18±8.08
Family history of epilepsy 0.003 0.957
With 34 29(85.29) 5(14.71)
Without 49 42(85.71) 7(14.29)
Production mode 0.111 0.738
Eutocia 52 45(86.54) 7(13.46)
Caesarean 31 26(83.87) 5(16.13)
Seizure type 6.200 0.013
Focal seizure 48 45(93.75) 3(6.25)
A generalized attack 35 26(74.29) 9(25.71)
Parental smoking history 0.002 0.964
With 41 35(85.37) 6(14.63)
Without 42 36(85.71) 6(14.29)
Parental drinking history 0.449 0.503
With 48 40(83.33) 8(16.67)
Without 35 31(88.57) 4(11.43)
Place of residence 0.105 0.746
Countryside 59 50(84.75) 9(15.25)
City 24 21(87.50) 3(12.50)
NGF (pg/ml) 5.166 <0.001
83 400.16±86.56 540.81±91.37
GABA (pg/ml) 2.442 0.016
83 462.37±83.23 400.44±67.31
NSE (ug/L) 12.60 <0.001
83 13.53±3.68 28.62±4.72
Treatment methods 6.938 <0.001
Sodium valproate therapy 40 30(75.00) 10(25.00)
Treatment of Sodium Valproate Combined with Levetiracetam 43 41(95.35) 2(4.65)